3 Essentials For A Fit-For-Purpose Compliance Strategy In Decentralized Pharma

April 1, 2022
By Penelope Przekop
Compliance
Quality
Quality Assurance
Consultants

We discuss three essentials for designing a compliance strategy to ensure patient safety and data integrity throughout the decentralized drug development process.

About the Author

Penelope Przekop, CEO

MSQA, RQAP-GCP

Penelope Przekop is a is a biopharmaceutical quality assurance and corporate compliance executive consultant with global R&D and commercial PV expertise. During the early 2000s, she developed and oversaw the first global PV quality and compliance departments established for Wyeth as well as Johson & Johnson. Her work includes qualification and oversight of numerous PV vendors covering all aspects of clinical safety and post-marketed PV. Penelope has facilitated numerous PV regulatory inspections. She frequently leads and conducts PV mock inspections and provides in-depth PV training.

How can we help you?

Reach out to schedule a consultation.